Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ami Takahashi

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials Communications|March 8, 2021
Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trialsAmi Takahashi, Taiji Suzuki
Pharmaceutical Statistics|December 1, 2020
Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trialsAmi Takahashi, Taiji Suzuki
The International Journal of Biostatistics|April 5, 2021
Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trialsAmi Takahashi, Taiji Suzuki
Plant Direct|May 7, 2025
UV-B Irradiation Does Not Promote Flowering in <i>Arabidopsis</i> Despite Increased <i>FT</i> ExpressionAmi Takahashi, Yuki Takahashi, Jun Hidema, et al.
The Journal of Toxicological Sciences|May 14, 2013
TO901317, a potent LXR agonist, is an inverse agonist of CARYuichiro Kanno, Nobuaki Tanuma, Ami Takahashi, et al.
International Immunopharmacology|July 5, 2017
Therapeutic application of human leukocyte antigen-G1 improves atopic dermatitis-like skin lesions in miceNaoyoshi Maeda, Chisato Yamada, Ami Takahashi, et al.
Scientific Reports|January 20, 2025
Enhanced effect of the immunosuppressive soluble HLA-G2 homodimer by site-specific PEGylationChisato Yamada, Kimiko Kuroki, Naoyoshi Maeda, et al.
International Journal of Molecular Sciences|November 30, 2019
Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G IsoformsAtsushi Furukawa, Manami Meguro, Rika Yamazaki, et al.
International Journal of Clinical Oncology|June 30, 2026
A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumorsNoboru Yamamoto, Gaurav Bajaj, Homer C Adams, et al.
Journal of Medical Microbiology|August 25, 2021
Emergence of a multidrug-resistant plasmid encoding <i>bla</i> <sub>NDM-1</sub>, <i>bla</i> <sub>OXA-420</sub> and <i>armA</i> in a clinical isolate of <i>Acinetobacter variabilis</i> in JapanKohei Uechi, Mari Tohya, Tatsuya Tada, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials Communications|March 8, 2021
Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trialsAmi Takahashi, Taiji Suzuki
Pharmaceutical Statistics|December 1, 2020
Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trialsAmi Takahashi, Taiji Suzuki
The International Journal of Biostatistics|April 5, 2021
Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trialsAmi Takahashi, Taiji Suzuki
Plant Direct|May 7, 2025
UV-B Irradiation Does Not Promote Flowering in <i>Arabidopsis</i> Despite Increased <i>FT</i> ExpressionAmi Takahashi, Yuki Takahashi, Jun Hidema, et al.
The Journal of Toxicological Sciences|May 14, 2013
TO901317, a potent LXR agonist, is an inverse agonist of CARYuichiro Kanno, Nobuaki Tanuma, Ami Takahashi, et al.
International Immunopharmacology|July 5, 2017
Therapeutic application of human leukocyte antigen-G1 improves atopic dermatitis-like skin lesions in miceNaoyoshi Maeda, Chisato Yamada, Ami Takahashi, et al.
Scientific Reports|January 20, 2025
Enhanced effect of the immunosuppressive soluble HLA-G2 homodimer by site-specific PEGylationChisato Yamada, Kimiko Kuroki, Naoyoshi Maeda, et al.
International Journal of Molecular Sciences|November 30, 2019
Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G IsoformsAtsushi Furukawa, Manami Meguro, Rika Yamazaki, et al.
International Journal of Clinical Oncology|June 30, 2026
A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumorsNoboru Yamamoto, Gaurav Bajaj, Homer C Adams, et al.
Journal of Medical Microbiology|August 25, 2021
Emergence of a multidrug-resistant plasmid encoding <i>bla</i> <sub>NDM-1</sub>, <i>bla</i> <sub>OXA-420</sub> and <i>armA</i> in a clinical isolate of <i>Acinetobacter variabilis</i> in JapanKohei Uechi, Mari Tohya, Tatsuya Tada, et al.
Pageof 2